Abstract
Introduction AKI is a heterogeneous syndrome defined via serum creatinine and urine output criteria. However, these markers are insufficient to capture the biological complexity of AKI and not necessarily inform on future risk of kidney and clinical events.
Methods Data from ASSESS-AKI was obtained and analyzed to uncover different clinical and biological signatures within AKI. We utilized a set of unsupervised machine learning algorithms incorporating a comprehensive panel of systemic and organ-specific biomarkers of inflammation, injury, and repair/health integrated into electronic data. Furthermore, the association of these novel biomarker-enriched subphenotypes with kidney and cardiovascular events and death was determined. Clinical and biomarker concentration differences among subphenotypes were evaluated via classic statistics. Kaplan-Meier and cumulative incidence curves were obtained to evaluate longitudinal outcomes.
Results Among 1538 patients from ASSESS-AKI, we included 748 AKI patients in the analysis. The median follow-up time was 4.8 years. We discovered 4 subphenotypes via unsupervised learning. Patients with AKI subphenotype 1 (‘injury’ cluster) were older (mean age ± SD): 71.2 ± 9.4 (p<0.001), with high ICU admission rates (93.9%, p<0.001) and highly prevalent cardiovascular disease (71.8%, p<0.001). They were characterized by the highest levels of KIM-1, troponin T, and ST2 compared to other clusters (P<0.001). AKI subphenotype 2 (‘benign’ cluster) is comprised of relatively young individuals with the lowest prevalence of comorbidities and highest levels of systemic anti-inflammatory makers (IL-13). AKI Subphenotype 3 (‘chronic inflammation and low injury’) comprised patients with markedly high pro-BNP, TNFR1, and TNFR2 concentrations while presenting low concentrations of KIM-1 and NGAL. Patients with AKI subphenotype 4 (‘inflammation-injury’) were predominantly critically ill individuals with the highest prevalence of sepsis and stage 3 AKI. They had the highest systemic (IL-1B, CRP, IL-8) and kidney inflammatory biomarker activity (YKL-40, MCP-1) as well as high kidney injury levels (NGAL, KIM-1). AKI subphenotype 3 and 4 were independently associated with a higher risk of death compared to subphenotype 2. Moreover, subphenotype 3 was independently associated with CKD outcomes and CVD events.
Conclusion We discovered four clinically meaningful AKI subphenotypes with statistical differences in biomarker composites that associate with longitudinal risks of adverse clinical events. Our approach is a novel look at the potential mechanisms underlying AKI and the putative role of biomarkers investigation.
Competing Interest Statement
SGC has salary support from NIH grants R01DK115562, UO1DK106962, R01HL085757, R01DK112258, R01DK126477 and UH3DK114920. SGC reports personal income and equity and stock options from Renalytix and pulseData; he also reports personal income from Axon Therapeutics, Bayer, Boehringer-Ingelheim, CHF Solutions, ProKidney, Vifor, and Takeda. EDS reports personal income from Akebia Therapeutics, Da Vita, and UpToDate; he also serves as an associate editor for the Clinical Journal of the American Society of Nephrology. CRP reports personal income and equity and stock options from Renaltyix; he also reports personal income from Genfit Biopharmaceutical Company and Akebia Therapeutics. E.M., C.R. and M.J.K. are employees of Randox but do not own shares in the company. The remaining authors declare that they have no relevant financial interests. GNN is supported by a career development award from the National Institutes of Health (K23DK107908) and is also supported by R01DK108803, U01HG007278, U01HG009610, and 1U01DK116100. Furthermore, GNN receives financial compensation as consultant and advisory board member for RenalytixAI, Inc, and owns equity in RenalytixAI. GNN is a scientific cofounder of RenalytixAI. Dr Nadkarni has received operational funding from Goldfinch Bio and consulting fees from BioVie Inc and GLG consulting in the past 3 years. WO is supported by Grant Number T32 DK007757 from NIH NIDDK. The remaining authors have no disclosures to report.
Funding Statement
The authors would like to thank all of the ASSESS-AKI study participants, research coordinators, and support staff for making this study possible. The ASSESS-AKI was supported by cooperative agreements from the NIDDK (U01DK082223, U01DK082185, U01DK082192, and U01DK082183). We also acknowledge funding support from NIH grants R01HL085757, R01DK098233, R01DK101507, R01DK114014, K23DK100468, R03DK111881, R01DK093771, K01DK120783, P30DK079310, and P30DK114809. The ARID study was funded by a grant from Kidney Research UK (RP13/2015). The funder did not have any role in study design, data collection, analysis, reporting, or the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Yale University gave ethical approval for this work Ethics committee/IRB of Washington University gave ethical approval for this work Ethics committee/IRB of Vanderbilt University gave ethical approval for this work Ethics committee/IRB of Icahn School of Medicine at Mount Sinai gave ethical approval for this work Ethics committee/IRB of University of California at San Francisco gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
